Evidence map›Paper›PMID 39766219›Full record

ArticleBiomolecules2024

Role of Nicotinamide in the Pathogenesis of Actinic Keratosis: Implications for NAD

Riccardo Belardi, Francesca Pacifici, Terenzio Cosio, Sara Lambiase, Ruslana Gaeta Shumak, Fabio Artosi, Antonia Rivieccio, Danilo Cavalloro, Elena Dellambra, Luca Bianchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Skin Cancer Prevention and Antiaging: Role of Nicotinamide.International journal of molecular sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Riccardo BelardiClinical Laboratory Medicine Unit, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Francesca PacificiClinical Laboratory Medicine Unit, Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0001-9014-7492
Terenzio CosioDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0003-4025-7882
Sara LambiaseDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Ruslana Gaeta ShumakDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Fabio ArtosiDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0002-7636-3532
Antonia RivieccioDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Danilo CavalloroDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Elena DellambraLaboratory of Tissue Engineering, Istituto Dermopatico dell'Immacolata, IRCCS, Via dei Monti di Creta, 104, 00167 Rome, Italy.ORCID 0000-0002-4329-3312
Luca BianchiDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0001-8697-6896
David Della-MorteDepartment of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, 00166 Rome, Italy.
Elena CampioneDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0001-7447-6798

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Actinic keratosis (AK) is a precursor to invasive squamous cell carcinoma, making early diagnosis and treatment essential to prevent progression. Among available therapeutic options, nicotinamide (NAM) has shown potential in reducing AK progression. NAM is a precursor of nicotinamide adenine dinucleotide (NAD

Indexed as

Keratosis, ActinicLeukocytes, MononuclearNADNiacinamideSirtuin 1AgedAged, 80 and overFemaleHumansMaleMiddle AgedSignal TransductionNADNiacinamideSIRT1 protein, humanSirtuin 1actinic keratosisNAD+sirtuin 1 activity

Identifiers

PMID39766219
PMCPMC11673244

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.